TABLE 2

Intracellular in vitro susceptibility testing

First author [ref.]	Strains	Cells	Method	Concentration range μg·mL⁻¹	Drugs	Cells	MIC	Δlog₁₀ CFU reduction^#
Luna-Herrera [39]	2 CI, MDR-TB	J774A.1 murine macrophages	GI	0.06–2.0	CLR			2–3^¶
	2 CI							2–3^¶
	1 H37Rv							2^¶
Rastogi [44]	H37Rv	PBMC-derived human macrophages	CFU counts	4 μg·mL⁻¹	CLR			<1
Falzari [47]	Erdman	J774A.1 murine macrophages	CFU counts	0.06, 0.32, 1.6, 8 μM	CLR			<1
Falzari [47]	Erdman	J774A.1 murine macrophages	CFU counts	0.06, 0.32, 1.6, 8 μM	CETH			<1
Tomioka [49]	Kurono MDR-TB	MM6	CFU counts	2.3 μg·mL⁻¹	CLR	MM6		1–2
Tomioka [49]	Kurono MDR-TB	A549-II				A549		1–2
Sato [48]	Kurono MDR-TB	MM6	CFU counts	2.3 μg·mL⁻¹	CLR	MM6		1–2
		A549-II				A549		2
			MIC determination			MM6 A549	5 μg·mL⁻¹ 2.5 μg·mL⁻¹

MIC: minimal inhibitory concentration; CI: clinical isolate; MDR-TB: multidrug-resistant tuberculosis; J774A.1: murine monocyte macrophage cell line; GI: growth index; CLR: clarithromycin; PBMC: peripheral blood monocytic cells; CETH: cethromycin; MM6: Mono-Mac-6 human monocytic cell line; A549-II: type II human alveolar epithelial cell lines. ^#: results are read from graphs, therefore a certain error must be taken into account; ^¶: not a log₁₀ CFU reduction but log₁₀ reduced growth measured using growth index.